Rezolute Q1 FY2023 net loss $9.8M; cash $154.3M; RZ358/402 advance

Rezolute, Inc.

2023-Q1 EPS reported -$0.19

Cash and equivalents $154.3M as of Sep 30, 2022; net loss $9.8M vs $7.8M YoY.
R&D expenses $7.7M (up 33% YoY); G&A $2.5M (up 32% YoY) on higher clinical and stock-based costs.
RZ358 Phase 2b showed ~75% reduction in hypoglycemia events; regulatory discussions underway for Phase 3.
RZ402 Phase 1b MAD data supports once-daily dosing; Phase 2 proof-of-concept study expected by end-2022.
Closed $130M financing post-quarter to advance both molecules into next clinical stages.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Rezolute, Inc. reported the first quarter of fiscal 2023 ended September 30, 2022 results: net income Net loss was $9.8 million for the first quarter of fiscal 2023.

Period: the first quarter of fiscal 2023 ended September 30, 2022
Net income: Net loss was $9.8 million for the first quarter of fiscal 2023
Result: reported results

Exact text from the filing

Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced its financial results for the first quarter of fiscal 2023 ended September 30, 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Rezolute, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-116477

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.